Takato Sasaki

Dr. Takato Sasaki

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
TATsubasa Aiyoshi
Tsubasa Aiyoshi
KMKouji Masumoto
Kouji Masumoto
NTNao Tanaka
Nao Tanaka
TSTakato Sasaki
Takato Sasaki
FCFumiko Chiba
Fumiko Chiba
SHShigemi Hitomi
Shigemi Hitomi
Aiyoshi T, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Nov;24(6):510-517. https://doi.org/10.5223/pghn.2021.24.6.510

1 January 2025 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
NKNORIKO KIMURA
NORIKO KIMURA
KMKoji Muroya
Koji Muroya
MYMasato Yonamine
Masato Yonamine
KTKazuhiro Takekoshi
Kazuhiro Takekoshi
TSTakeshi Sato
Takeshi Sato
TKTakuyuki Katabami
Takuyuki Katabami
Pediatric patients with pheochromocytoma (PCC)/paraganglioma (PGL) (PPGL) are rare, and clinicopathological investigations, especially the relationship between gene analysis and histological features, are insufficient. We comprehensively examined the clinical data, germline/somatic variants (mutations), and pathological characteristics of operated tumors using immunohistochemical expression and histological grading by Grading of Adrenal PCC and PGL score. This study included 28 patients (15 males and 13 females) aged <19 years. The age at the diagnosis was 12.8 ± 4.5 years. The included patient often had multiple PPGLs, with 39 tumors, including 21 PCCs and 18 PGLs, with average tumor sizes of 45.0 ± 22.8 and 42.6 ± 23.6 mm, respectively. Genomic types examined by gene mutations and immunohistochemistry of CA9 for VHL, SDHB for SDHx, and MAX for MAX, classified them into 14 VHL (50%), ten SDHx (35.7%), one MAX (3.6%), and three unknown (10.7%) types. Tumor metastasis was limited to two SDHB-related PPGLs, but not to VHL-related PPGLs. In both patients, the metastatic sites were the bones. The average GAPP score of the PPGLs was 2.9 ± 1.5 in VHL and 5.3 ± 1.7 in SDHB, and histological grades were well-differentiated in VHL and moderately differentiated in SDHB. SSTR2 expression was positive in 90% of SDHB-related PPGLs, but negative in 75% and weakly or focally positive in 25% of VHL-related PPGLs. Most pediatric PPGLs (90%) demonstrated mutations in VHL, SDHB, and MAX, with histological features depending on the mutation type. Combined genetic and immunohistochemical examination is desirable for accurate genomic diagnosis, and clinicopathological study.

24 July 2025 in Children
Verified
Journal Article
Open access
PDF file
YGYudai Goto
Yudai Goto
KMKouji Masumoto
Kouji Masumoto
TSTakato Sasaki
Takato Sasaki
KSKazuki Shirane
Kazuki Shirane
TATomohiro Aoyama
Tomohiro Aoyama
TJTakahiro Jimbo
Takahiro Jimbo
Background/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this interpretation may vary depending on the remnant bowel anatomy. Methods: We conducted a retrospective case series of four pediatric patients with SBS (aged < 15 years) who received teduglutide for 12 months at our hospital between 2018 and 2023. Changes in plasma citrulline levels and parenteral nutrition requirements were assessed in addition to bowel anatomy classification. Results: This study included two males and two females. All patients showed an increase in plasma citrulline levels and a reduction in the requirement for parenteral nutrition (PN) after 12 months of teduglutide treatment. In SBS type 2 (jejunocolic anastomosis), citrulline levels increased by 114% and 52%, with PN reduction rates of 100% and 30%, respectively. In SBS type 3 (jejunoileal anastomosis), citrulline levels increased by 13.6% and 34%, with PN reductions of 33% and 73%, respectively. Conclusions: Teduglutide treatment increased plasma citrulline levels and reduced PN levels in all cases. However, the magnitude of the citrulline change varied across bowel anatomy types, suggesting that the anatomical difference in the remnant bowel may influence the biomarker response. Further detailed pediatric cases are required to clarify the role of citrulline in evaluating GLP-2 analogue treatment outcomes.

18 July 2025 in Journal of Pediatric Surgery Open
Verified
Journal Article
Open access
KSKazuki Shirane
Kazuki Shirane
TSToko Shinkai
Toko Shinkai
HSHinako Sakai
Hinako Sakai
TATomohiro Aoyama
Tomohiro Aoyama
YGYudai Goto
Yudai Goto
KMKouji Masumoto
Kouji Masumoto

27 December 2025 in Pediatrics International
Verified
Journal Article
Open access
KMKouji Masumoto
Kouji Masumoto
MMMitsuru Muto
Mitsuru Muto
TSTakato Sasaki
Takato Sasaki
MSMitsuhiro Shikamura
Mitsuhiro Shikamura
TTTomoko Tanaka
Tomoko Tanaka
SISatoshi Ieiri
Satoshi Ieiri
Background: Patients with short bowel syndrome (SBS)‐associated intestinal failure (SBS‐IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP‐2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. This study evaluated the safety and efficacy of teduglutide in Japanese pediatric patients with SBS‐IF (dependence on PS to provide ≥30% of fluid or caloric intake needs) who weighed less than 10 kg. Methods: This phase 3, open‐label study enrolled Japanese pediatric patients with SBS‐IF. Patients weighing less than 10 kg received teduglutide 0.05 mg/kg/day subcutaneously in 28‐week treatment cycles (24 weeks of teduglutide treatment and 4 weeks of follow‐up). Adverse events, changes in PS requirements, and growth parameters were assessed. Results: Three patients completed the study, with a mean teduglutide exposure duration of 48.9 weeks. All patients experienced treatment‐emergent adverse events (TEAEs), but none were related to the study drug or led to death or treatment discontinuation. Clinically meaningful reductions in mean PS volume (13.1%) and mean PS caloric intake (46.6%) were observed at the end of treatment from baseline. One patient achieved a reduction in PS volume of ≥20% at the end of treatment from baseline. Growth parameters showed increases in weight and height/length‐for‐age z ‐scores at the end of treatment from baseline. Conclusion: In the three patients with SBS‐IF who weighed less than 10 kg, no new safety signals were observed following teduglutide treatment. Clinically meaningful reductions in PS were noted and there was no adverse impact on growth parameters. Trial Registration: ClinicalTrials.gov registration number: NCT05027308

9 October 2025 in Children
Verified
Journal Article
Open access
PDF file
YGYudai Goto
Yudai Goto
KMKouji Masumoto
Kouji Masumoto
TSTakato Sasaki
Takato Sasaki
YUYasuhisa Urita
Yasuhisa Urita
KSKazuki Shirane
Kazuki Shirane
KUKatsuhiko Ueoka
Katsuhiko Ueoka
Background/Objectives: Transurethral incision (TUI) is a common procedure for posterior urethral valves (PUV). However, no standardized method has been established to assess its efficacy intraoperatively. In this study, we aimed to develop and evaluate a real-time ultrasound-guided TUI (RUG-TUI) technique. Methods: A single-center, retrospective feasibility study with a cohort design was conducted using historical controls to compare RUG-TUI with standard TUI in children with PUV. Data from patients who underwent RUG-TUI for PUV between April 2021 and July 2022 or TUI without real-time ultrasound guidance between August 2020 and March 2021 (control group) were retrospectively reviewed. A transperineal linear probe provided longitudinal imaging. The diameters of the constricted (C) and expanded (E) portions of the urethra before and after the procedure were measured, and the E/C ratio was calculated. The primary outcome was the duration of postoperative gross hematuria, and the secondary outcomes included changes in the urethral diameter ratio (E/C ratio), intraoperative complications, and residual obstruction on VCUG. Results: The mean duration of post-procedure macroscopic hematuria was significantly shorter in the RUG-TUI group than in the control group (p = 0.049). No massive intraoperative bleeding or sphincter damage occurred. In the RUG-TUI group, the mean diameters of the constricted segment before and after the procedure were 3.0 (±1.0) and 5.7 (±1.2) mm, respectively, while the pre- and postoperative E/C ratios were 1.8 (±0.5) and 0.9 (±0.1), respectively (p < 0.0001). Conclusions: RUG-TUI for PUV enabled visualization of the longitudinal axis of the urethra, allowing assessment of the anatomical relationship between the stenosis and external urethral sphincter. In this retrospective feasibility cohort, RUG-TUI was associated with a shorter duration of postoperative gross hematuria. These exploratory findings suggest that RUG-TUI may support intraoperative evaluation of procedural adequacy.